Uçar Fatih M, Açar Burak
Department of Cardiology, Trakya University Hospital, Edirne, Turkey. E-mail.
Saudi Med J. 2017 Feb;38(2):143-148. doi: 10.15537/smj.2017.2.15929.
To investigate whether an inflammatory marker of neutrophil to lymphocyte ratio (NLR) predicts appropriate implantable cardioverter defibrillator (ICD) therapy (shock or anti tachycardia pacing) in idiopathic dilated cardiomyopathy (IDC) patients.
We retrospectively examined IDC patients (mean age: 58.3 ± 11.8 years, 81.5% male) with ICD who admitted to outpatient clinic for pacemaker control at 2 tertiary care hospitals in Ankara and Edirne, Turkey from January 2013-2015. All ICDs were implanted for primary prevention. Hematological and biochemical parameters were measured prior procedure. Results: Over a median follow-up period of 43 months (Range 7-125), 68 (33.1%) patients experienced appropriate ICD therapy. The NLR was increased in patients that received appropriate therapy (4.39 ± 2.94 versus 2.96 ± 1.97, p less than 0.001).To identify independent risk factors for appropriate therapy, a multivariate linear regression model was conducted and age (β=0.163, p=0.013), fasting glucose (β=0.158, p=0.017), C-reactive protein (CRP) (β=0.289, p less than 0.001) and NLR (β=0.212, p less than 0.008) were found to be independent risk factors for appropriate ICD therapy. Conclusions: Before ICD implantation by using NLR and CRP, arrhythmic episodes may be predictable and better antiarrhythmic medical therapy optimization may protect these IDC patients from unwanted events.
探讨中性粒细胞与淋巴细胞比值(NLR)这一炎症标志物能否预测特发性扩张型心肌病(IDC)患者接受合适的植入式心律转复除颤器(ICD)治疗(电击或抗心动过速起搏)。
我们回顾性研究了2013年1月至2015年期间在土耳其安卡拉和埃迪尔内的2家三级护理医院门诊接受起搏器程控的植入ICD的IDC患者(平均年龄:58.3±11.8岁,81.5%为男性)。所有ICD均用于一级预防。术前测量血液学和生化参数。结果:在中位随访期43个月(范围7 - 125个月)内,68例(33.1%)患者接受了合适的ICD治疗。接受合适治疗的患者NLR升高(4.39±2.94 vs 2.96±1.97,p<0.001)。为确定合适治疗的独立危险因素,进行了多因素线性回归模型分析,发现年龄(β = 0.163,p = 0.013)、空腹血糖(β = 0.158,p = 0.017)、C反应蛋白(CRP)(β = 0.289,p<0.001)和NLR(β = 0.212,p<0.008)是合适ICD治疗的独立危险因素。结论:在植入ICD前,通过使用NLR和CRP,心律失常发作可能是可预测的,更好地优化抗心律失常药物治疗可能使这些IDC患者免受不良事件影响。